Disease-A-Month
Volume 55, Issue 5 , Pages 263-291 , May 2009

Food Contamination

References 

  1. Biberoglu S, Biberoglu K, Komsuoglu G. Mad honey. JAMA. 1988;259:1943
  2. Head T, Landes R. The peace of God: social violence and religious response in France around the year 1000. Speculum. 1994;69:163–169
  3. Woolf A. Witchcraft or mycotoxin? (The Salem witch trials). J Toxicol Clin Toxicol. 2000;38:457–460
  4. Emmerson BT. “Ouch-ouch” disease: the osteomalacia of cadmium nephropathy. Ann Intern Med. 1970;73:854–855
  5. Bakir F, Damluji SF, Amin-Zaki L, et al. Methyl mercury poisoning in Iraq. Science. 1973;181:230–241
  6. Smith HV, Spalding JM. Outbreak of paralysis in Morocco due to ortho-cresyl phosphate poisoning. Lancet. 1959;2:1019–1021
  7. Kuratsune M, Yoshimura T, Matsuzaka J, et al. Epidemiologic study of polychlorinated biphenyls. Environ Health Perspect. 1972;1:119–128
  8. Chen PH, Wong CK, Rappe C, et al. Polychlorinated biphenyls, dibenzofurans and quaterphenyls in toxic rice-bran oil and in the blood and tissues of patients with PCB poisoning (Yu-cheng) in Taiwan. Environ Health Perspect. 1985;59:59–65
  9. Kuratsune M, Yoshimura H, Hori Y, et al. Yusho—a human disaster caused by PCB and related compounds. Fukuoka: Kyushu University Press; 1996;
  10. Yoshimura T. Yusho in Japan. Ind Health. 2003;41:139–148
  11. Kunita N, Kashimoto T, Miyata H, et al. Causal agents of yusho. Prog Clin Biol Res. 1984;137:45–58
  12. Kashimoto T, Miyata H, Fukushima S, et al. PCBs, PCQs and PCDFs in the blood of Yusho and Yu-cheng patients. Environ Health Perspect. 1985;59:73–78
  13. Guo YL, Lambert HG, Hsu C-C, et al. Yucheng: health effects of prenatal exposure to polychlorinated biphenyls and dibenzofurans. Int Arch Occup Environ Health. 2004;77:153–158
  14. Asahi M. Clinical features and pathogenesis of Yusho (PCB poisoning). J Univ Occup Environ Health. 1993;15:1–11
  15. Yoshimura T. Epidemiological analysis of “yusho” patients with special reference to sex, age, clinical grades and oil consumption. Fukuoka Acta Medica. 1971;62:104–108
  16. Hayabuchi H, Yoshimura T, Kuratsune M. Consumption of toxic rice oil by Yusho patients and its relation to the clinical response and latent period. Food Cosmet Toxicol. 1979;17:455–461
  17. Miyata H, Fukushima S, Kashimoto T, et al. PCBs, PCQs and PCDFs in tissues of yusho and yu-cheng patients. Environ Health Perspect. 1985;59:67–72
  18. Yoshimura T, Hayabuchi H. Relationship between the amount of rice oil ingested by patients with yusho and their subjective symptoms. Environ Health Perspect. 1985;59:47–51
  19. Masuda Y. Health status of Japanese and Taiwanese after exposure to contaminated rice oil. Environ Health Perspect. 1985;60:321–325
  20. Norback DH, Weltman RH. Polychlorinated biphenyl induction of hepatocellular carcinoma in the Sprague-Dawley rat. Environ Health Perspect. 1985;60:97–105
  21. Hirota Y, Tokunaga S, Kataoka K, et al. Symptoms and blood PCB level among chronic yusho patients, twenty-five years after outbreak. Fukuoka Igaku Zasshi. 1997;88:220–225
  22. Yoshimura T. Epidemiological study on yusho babies born to mothers who had consumed oil contaminated by PCB. Fukuoka Acta Medica. 1974;65:74–80
  23. Lu YC, Wong PN. Dermatological, medical, and laboratory findings of patients in Taiwan and their treatments. Am J Ind Med. 1984;5:81–115
  24. Fein GG, Jacobson JL, Jacobson SW, et al. Prenatal exposure to polychlorinated biphenyls: effects on birth size and gestational age. J Pediatrics. 1984;105:315–320
  25. Gladen BC, Rogan WJ. Decrements on six month and one-year Bayley scores and prenatal polychlorinated biphenyls (PCB) exposure. Am J Epidemiol. 1988;128:912
  26. Yang C-Y, Yu M-L, Guo M-L, et al. The endocrine and reproductive function of the female yu-cheng adolescents prenatally exposed to PCBs/PCDFs. Chemosphere. 2005;61:355–360
  27. Jacobson SW, Fein GG, Jacobson JL, et al. The effect of intrauterine PCB exposure on visual recognition memory. Child Dev. 1985;56:853–860
  28. Rogan WJ, Gladen BC, Hung KL, et al. Congenital poisoning by polychlorinated biphenyls and their contaminants in Taiwan. Science. 1988;241:334–336
  29. Tsai PC, Ko YC, Huang W, et al. Increased liver and lupus mortalities in 24-year follow-up of the Taiwanese people highly exposed to polychlorinated biphenyls and dibenzofurans. Sci Total Environ. 2007;374:216–222
  30. Hori T, Tobiishi K, Ashizuka Y, et al. Congener specific determination of PCBs in human blood using gel permeation chromatography (GPC) and high resolution gas chromatography/high resolution mass spectrometry (HRGC/HRMS). Fukuoka Igaku Zasshi. 2005;96:220–226
  31. Calaf RE, Pena J, Paytubi S, et al. Determination of aniline derivatives in oils related to the toxic oil syndrome by atmospheric pressure ionization-tandem mass spectrometry. Anal Chem. 2001;73:3828–3837
  32. Chen PH, Luo ML, Wong CK, et al. Polychlorinated biphenyls, dibenzofurans, and quaterphenyls in the toxic rice-bran oil and PCBs in the blood of patients with PCB poisoning in Taiwan. Am J Ind Med. 1984;5:133–145
  33. Nagayama J, Masuda Y, Kuratsune M. Determination of polychlorinated dibenzofurans in tissues of patients with Yusho. Food Cosmet Toxicol. 1977;15:195–198
  34. Lung S-C, Guo Y-L, Chang H-Y. Serum concentrations and profiles of polychlorinated biphenyls in Taiwan Yu-cheng victims twenty years after the incident. Environ Pollut. 2005;136:71–79
  35. Ryan JJ, Levesque D, Panopio LG, et al. Elimination of polychlorinated dibenzofurans (PCDFs) and polychlorinated biphenyls (PCBs) from human blood in the yusho and yu-cheng rice oil poisonings. Arch Environ Contam Toxicol. 1993;24:504–512
  36. Imamura T, Kanagawa Y, Matsumoto S, et al. Relationship between clinical features and blood levels of pentachlorodibenzofuran in patients with yusho. Environ Toxicol. 2007;22:124–131
  37. Todaka T, Hirakawa H, Hori T, et al. Concentrations of polychlorinated dibenzo-p-dioxins, polychlorinated dibenzofurans, and non-ortho and mono-ortho polychlorinated biphenyls in the blood of Yusho patients. Chemosphere. 2007;66:1983–1989
  38. Masuda Y, Yoshimura H. Polychlorinated biphenyls and dibenzofurans in patients with yusho and their toxicological significance: a review. Am J Ind Med. 1984;5:31–44
  39. Posada de la Paz M, Philen RM, Abaitua Borda I. Toxic oil syndrome: the perspective after 20 years. Epidemiol Rev. 2001;23:231–247
  40. Posada de la Paz M, Philen RM, Abaitua Borda I, et al. Manufacturing processes at two French rapeseed oil companies: possible relationships to toxic oil syndrome in Spain. Food Chem Toxicol. 1991;29:797–803
  41. Rigau-Perez JG, Perez-Alvarez L, Duenas-Castro S, et al. Epidemiologic investigation of an oil-associated pneumonic paralytic eosinophilic syndrome in Spain. Am J Epidemiol. 1984;119:250–260
  42. Posada M, Castro M, Kilbourne EM, et al. Toxic-oil syndrome: case reports associated with the ITH oil refinery in Seville. Food Chem Toxicol. 1987;25:87–90
  43. Reig N, Calaf RE, Messeguer A, et al. LC-MS ion maps for the characterization of aniline derivatives of fatty acids and triglycerides in laboratory-denatured rapeseed oil. J Mass Spectrom. 2007;42:527–541
  44. Hard GC. Short-term adverse effects in humans of ingested mineral oils, their additives and possible contaminants—a review. Hum Exp Toxicol. 2000;19:158–172
  45. Closa D, Folch E, Calaf RE, et al. Absorption and effects of 3-(N-phenylamino)-1,2-propanediol esters in relation to toxic oil syndrome. Lipids. 2001;36:1125–1133
  46. Guitart R, Norgaard L, Abaitua Borda I, et al. Pentachlorophenol and pentachloroanisole in oil samples associated with the toxic oil syndrome. Bull Environ Contam Toxicol. 1999;62:1–7
  47. Morato A, Escabros J, Manich A, et al. On the generation and outcome of 3-(N-phenylamino)propane-1,2-diol derivatives in deodorized model oils related to toxic oil syndrome. Chem Res Toxicol. 2005;18:665–674
  48. Ruiz-Mendez MV, Posada de la Paz M, Abian J, et al. Storage time and deodorization temperature influence the formation of aniline-derived compounds in denatured rapeseed oils. Food Chem Toxicol. 2001;39:91–96
  49. Posada de la Paz M, Abaitua Borda I, Kilbourne EM, et al. Late cases of toxic oil syndrome: evidence that the aetiological agent persisted in oil stored for up to one year. Food Chem Toxicol. 1989;27:517–521
  50. Kilbourne EM, Bernert JT, Posada de la Paz M, et al. Chemical correlates of pathogenicity of oils related to the toxic oil syndrome epidemic in Spain. Am J Epidemiol. 1988;127:1210–1227
  51. Doll R. The aetiology of the Spanish Toxic Syndrome: interpretation of the epidemiological evidence. SPA/CEH 502. Copenhagen, Denmark: World Health Organization; 1985;
  52. Tabuenca JM. Toxic-allergic syndrome caused by ingestion of rapeseed oil denatured with aniline. Lancet. 1981;2:567–568
  53. Grandjean P, Tarkowsky S. Review of investigations and findings. In: World Health Organization: Toxic Oil Syndrome: Mass Food Poisoning in Spain. 1st ed.. Copenhagen, Denmark: WHO, Regional Office for Europe; 1984;p. 3–16
  54. World Health Organization. Report on the 21st Meeting of the WHO/FIS Scientific Committee for the Toxic Oil Syndrome. Copenhagen, Denmark: WHO; 1997;
  55. Abaitua Borda I, Philen RM, Posada de la Paz M, et al. Toxic oil syndrome mortality: the first 13 years. Int J Epidemiol. 1998;27:1057–1063
  56. Diaz de Rojas F, Castro Garcia M, Abaitua Borda I, et al. The association of oil ingestion with toxic oil syndrome in two convents. Am J Epidemiol. 1987;125:907–911
  57. Kaufman LD, Krupp LB. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia. Curr Opin Rheumatol. 1995;7:560–567
  58. Kilbourne EM, Rigau-Perez JG, Heath CW, et al. Clinical epidemiology of toxic-oil syndrome (Manifestations of a new illness). N Engl J Med. 1983;309:1408–1414
  59. Martinez-Tello FJ, Navas-Palacios JJ, Ricoy JR, et al. Pathology of a new toxic syndrome caused by ingestion of adulterated oil in Spain. Virchows Arch A Pathol Anat Histol. 1982;397:261–285
  60. Alonso-Ruiz A, Zea-Mendoza AC, Salazar-Vallinas JM, et al. Toxic oil syndrome: a syndrome with features overlapping those of various forms of scleroderma. Semin Arthritis Rheum. 1986;15:200–212
  61. Escribano PM, Diaz de Atauri MJ, Gomez Sanchez MA. Persistence of respiratory abnormalities four years after the onset of toxic oil syndrome. Chest. 1991;100:336–339
  62. James TN, Posada de la Paz M, Abaitua Borda I, et al. Histologic abnormalities of large and small coronary arteries, neural structures, and the conduction system of the heart found in postmortem studies of individuals dying from the toxic oil syndrome. Am Heart J. 1991;121:803–815
  63. Abaitua Borda I, Kilbourne EM, Posada de la Paz M, et al. Mortality among people affected by toxic oil syndrome. Int J Epidemiol. 1993;22:1077–1084
  64. Tello de Meneses R, Gomez de la Camara A, Nogales-Moran MA, et al. Pulmonary hypertension during exercise in toxic oil syndrome. Med Clin Barc. 2005;19:685–688
  65. Martin-Arribas MC, De Andres Copa P, De La Paz MP. Quality of life, disability and handicap in patients with toxic oil syndrome. J Adv Nurs. 2005;50:595–604
  66. Gomez de la Camara A, Posada de la Paz M, Abaitua Borda I, et al. Heath status measurement in toxic oil syndrome. J Clin Epidemiol. 1998;51:867–873
  67. Cardaba B, Gallardo S, Del Pozo V, et al. DR2 antigens are associated with severity of disease in toxic oil syndrome (TOS). Tissue Antigens. 2000;55:110–117
  68. Ladona MG, Izquierdo-Martinez M, Posada de La Paz MP, et al. Pharmacogenetic profile of xenobiotic enzyme metabolism in survivors of the Spanish toxic oil syndrome. Environ Health Perspect. 2001;109:369–375
  69. Hill RH, Schurz HH, Posada de la Paz M, et al. Possible etiologic agents for toxic oil syndrome: fatty acid esters of 3-(N-phenylamino)-1,2-propanediol. Arch Environ Contam Toxicol. 1995;28:259–264
  70. Posada de la Paz M, Philen RM, Abaitua Borda I, et al. Factors associated with pathogenicity of oils related to the toxic oil syndrome epidemic in Spain. Epidemiology. 1994;5:404–409
  71. Posada de la Paz M, Philen RM, Schurz H, et al. Epidemiologic evidence for a new class of compounds associated with toxic oil syndrome. Epidemiology. 1999;10:130–134
  72. Martinez-Cabot A, Morato A, Messeguer A. Synthesis and stability studies of the glutathione and N-acetylcysteine adducts of an iminoquinone reactive intermediate generated in the biotransformation of 3-(N-phenylamino)propane-1,2-diol: implications for toxic oil syndrome. Chem Res Toxicol. 2005;18:1721–1728
  73. Gallardo S, Cardaba B, del Pozo V, et al. Study of apoptosis in human lymphocytes by toxic substances implicated in toxic oil syndrome. Toxicol. 1997;118:71–82
  74. Gallardo S, Cardaba B, Posada M, et al. Toxic oil syndrome: genetic restriction and immunomodulatory effects due to adulterated oils in a model of HLA transgenic mice. Toxicol Lett. 2005;159:173–181
  75. Hayashi T, James TN. Immunohistochemical analysis of lymphocytes in postmortem study of the heart from fatal cases of the eosinophilia myalgia syndrome and of the toxic oil syndrome. Am Heart J. 1994;127:1298–1308
  76. Esteban A, Guerra L, Ruiz-Santana S, et al. ARDS due to ingestion of denatured rapeseed oil. Chest. 1983;84:166–169
  77. Gelpi E, de la Paz MP, Terracini B, et al. WHO/CISAT Scientific Committee for the Toxic Oil Syndrome, Centro de Investigacion para el Sindrome del Aceite Toxico: the Spanish toxic oil syndrome 20 years after its onset: a multidisciplinary review of scientific knowledge. Environ Health Perspect. 2002;110:457–464
  78. Gomez-Sanchez MA, Mestre de Juan MJ, Gomez-Pajuelo C, et al. Pulmonary hypertension due to toxic oil syndrome (A clinicopathologic study). Chest. 1989;95:325–331
  79. Gomez de la Camara A, Gomez Mateos MA, Ferrando Vivas P, et al. Prevalence of cardiovascular risk factors in a cohort affected by the toxic oil syndrome. Med Clin Barc. 2003;121:405–407[Spanish]
  80. Plaza Cano MM, Garcia de Albeniz Martinez XA, De Andres Copa P, et al. Diagnostic performance of echocardiography in the follow-up of patients with toxic oil syndrome. Rev Esp Cardiol. 2003;56:1195–1201
  81. Kaufman LD, Krupp LB. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia. Curr Opin Rheumatol. 1995;7:560–567
  82. Sanchez-Porro Valades P, Posada de la Paz M, de Andres Copa P, et al. Toxic oil syndrome: survival in the whole cohort between 1981 and 1995. J Clin Epidemiol. 2003;56:701–708
  83. Lyon IB. Textbook of medical jurisprudence of India. In: 1st ed.. Calcutta, India: Thacker, Spink & Company; 1889;p. 214
  84. Gomber S, Daral TS, Sharma PP, et al. Resurgence of epidemic dropsy. Indian Pediatr. 1997;34:953–957
  85. Khanna SK, Upreti KK, Singh GB. Trend of adulteration of mustard oil in rural markets of Uttar Pradesh. Sci Cult. 1986;52:149–156
  86. Verma SK, Dev G, Tyagi AK, et al. Argemone mexicana poisoning: autopsy findings of two cases. Forensic Sci Int. 2001;115:135–141
  87. Newton SM, Lau C, Gurcha SS, et al. The evaluation of forty-three plant species for in vitro antimycobacterial activities; isolation of active constituents from Psoralea corylifolia and Sanguinaria canadensis. J Ethnopharmacol. 2002;79:57–67
  88. Chakravarty NK, Chaudhuri RN, Werner G. Observations on vascular changes produced by Argemone alkaloids. Indian J Med Res. 1955;43:107–112
  89. Tandon S, Das M, Khanna SK. Biometabolic elimination and organ retention profile of Argemone alkaloid, sanguinarine, in rats and guinea pigs. Drug Metab Disp. 1993;21:194–197
  90. Pitts BJR, Meyerson LR. Inhibition of Na+-K+-ATPase activity and ouabain binding of sanguinarine. Drug Dev Res. 1981;1:43–47
  91. Upreti KK, Das M, Khanna SK. Biochemical toxicology of argemone oil: effect on hepatic cytochrome P-450 and xenobiotic metabolizing enzymes. J Appl Toxicol. 1991;11:203–209
  92. Upreti KK, Das M, Kumar A, et al. Biochemical toxicology of argemone oil (IV. Short-term oral feeding response in rats). Toxicol. 1989;58:285–298
  93. Tandon S, Das M, Khanna SK. Effect of sanguinarine on the transport of essential nutrients in an everted gut sac model: role of Na+-K+-ATPase. Nat Toxins. 1993;1:235–240
  94. Das M, Babu K, Reddy NP, et al. Oxidative damage of plasma proteins and lipids in epidemic dropsy patients: alterations in antioxidant status. Biochim Biophys Acta. 2005;1722:209–217
  95. Lal RB, Dasgupta AC. Investigation into epidemiology of epidemic dropsy X: a note on an outbreak of epidemic dropsy associated with the use of mustard oil pressed from adulterated seed. Indian J Med Res. 1941;29:157–163
  96. Das M, Khanna SK. Clinicoepidemiological, toxicological, and safety evaluation studies on argemone oil. Crit Rev Toxicol. 1997;27:273–297
  97. Kar HK, Jain RK, Sharma PK, et al. Epidemic dropsy: a study of cutaneous manifestations with histopathological correlation. Indian J Venereol Leprol. 2001;67:178–179
  98. Sood NN, Sachdev MS, Verma LK. Pressure dynamics and treatment modalities of epidemic dropsy glaucoma. Glaucoma. 1990;12:20–27
  99. Sachdev HP, Sachdev MS, Verma L, et al. Electrophysiological studies of the eye, peripheral nerves and muscles in epidemic dropsy. J Trop Med Hyg. 1989;92:412–415
  100. Sharma BD, Bhatia V, Rahtee M, et al. Epidemic dropsy: observations on pathophysiology and clinical features during the Delhi epidemic of 1998. Trop Doct. 2002;32:70–75
  101. Singh K, Singh MJ, Das JC. Visual field defects in epidemic dropsy. Clin Toxicol. 2006;44:159–163
  102. Singh NP, Anuradha S, Dhanwal DK, et al. Epidemic dropsy—a clinical study of the Delhi outbreak. J Assoc Physicians India. 2000;48:877–880
  103. Sachdev MS, Sood NN, Verma LK, et al. Pathogenesis of epidemic dropsy glaucoma. Arch Ophthalmol. 1988;106:1221–1223
  104. Malik KP, Dadeya S, Gupta VS, et al. Pattern of intraocular pressure in epidemic dropsy in India. Trop Doct. 2004;34:161–162
  105. Prakash J. Acute renal failure in epidemic dropsy. Ren Fail. 1999;21:707–711
  106. Tandon RK, Tandon HD, Nayak NC, et al. Liver in epidemic dropsy. Ind J Med Res. 1976;64:1064–1069
  107. Senegupta PC, Napier LE. Haematological changes in epidemic dropsy. Ind J Med Res. 1940;28:197–203
  108. Chopra RN, Basu VP. Cardiovascular manifestations of epidemic dropsy and their treatment. Ind Med Gaz. 1980;65:546–550
  109. Singh GB, Khanna SK. Argemone mexicana strikes again. Sci Rep. 1983;20:108–110
  110. Husain S, Narsimha R, Rao RN. Separation, identification and determination of sanguinarine in argemone and other adulterated edible oils by reversed-phase high-performance liquid chromatography. J Chromatogr Anal. 1999;863:123–126
  111. Tandon RK, Singh DS, Arora RR, et al. Epidemic dropsy in New Delhi. Am J Clin Nutr. 1975;28:883–887
  112. Das M, Babu K, Reddy NP, et al. Oxidative damage of plasma proteins and lipids in epidemic dropsy patients: alterations in antioxidant status. Biochim Biophys Acta. 2005;1722:209–217
  113. Khilnani GC, Trikha I, Malhotra OP, et al. Pulmonary functions in patients with epidemic dropsy. Indian J Chest Dis Allied Sci. 2003;45:25–29
  114. Upreti KK, Das M, Khanna SK. Role of antioxidants and scavengers on argemone oil induced toxicity. Arch Environ Contam Toxicol. 1991;20:531–537
  115. Singh K, Singh MJ, Das JC. Visual field defects in epidemic dropsy. Clin Toxicol. 2006;44:159–163
  116. Sainani GS. Epidemic dropsy. In:  Ahuja MM editors. Progress in Clinical Medicine in India. New Dehli, India: Arnold Heinemann Publishers; 1976;p. 92–104
  117. Sternberg EM, Van Woert MH, Young SN, et al. Development of a scleroderma-like illness during therapy with l-5-hydroxytryptophan and carbidopa. N Engl J Med. 1980;303:782–787
  118. Swygert LA, Maes EF, Sewell LE, et al. Eosinophilia-myalgia syndrome (Results of national surveillance). JAMA. 1990;264:1698–1703
  119. Hertzman PA, Blevins WL, Mayer J, et al. Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. N Engl J Med. 1990;322:869–873
  120. Kilbourne EM, Philen RM, Kamb ML, et al. Tryptophan produced by Showa Denko and epidemic eosinophilia-myalgia syndrome. J Rheumatol. 1996;23(suppl 46):81–88
  121. McKeon P, Swanwick G, Manley P. l-Tryptophan and the eosinophilia-myalgia syndrome: a clinical and laboratory study. Acta Psychiatr Scand. 1993;90:451–454
  122. Sullivan EA, Staehling N, Philen RM. Eosinophilia-myalgia syndrome among the non-l-tryptophan users and pre-epidemic cases. J Rheumatol. 1996;23:1784–1787
  123. Naylor S, Williamson BL, Johnson KL, et al. Structural characterization of case-associated contaminants peak C and FF in l-tryptophan implicated in eosinophilia-myalgia syndrome. Adv Exp Med Biol. 1999;467:453–460
  124. Hill RH, Caudill SP, Philen RM, et al. Contaminants in l-tryptophan associated with eosinophilia myalgia syndrome. Arch Environ Contam Toxicol. 1993;25:134–142
  125. Philen RM, Posada M. Toxic oil syndrome and eosinophilia-myalgia syndrome: May 8-10, 1991, World Health Organization Meeting Report. Semin Arthritis Rheum. 1993;23:104–124
  126. Philen RM, Hill RH, Flanders WD, et al. Tryptophan contaminants associated with eosinophilia-myalgia syndrome. Am J Epidemiol. 1993;138:154–159
  127. Mayeno AN, Benson LM, Naylor S, et al. Biotransformation of 3-(phenylamino)-1,2-propanediol to 3-(phenylamino)alanine: a chemical link between toxic oil syndrome and eosinophilia-myalgia syndrome. Chem Res Toxicol. 1995;8:911–916
  128. Martinez-Cabot A, Messeguer A. Generation of quinoneimine intermediates in the bioactivation of 3(N-phenylamino)alanine (PAA) by human liver microsomes: a potential link between eosinophilia-myalgia syndrome and toxic oil syndrome. Chem Res Toxicol. 2007;20:1556–1562
  129. Sato F, Hagiwara Y, Kawase Y. Subchronic toxicity of 3-phenylamino alanine, an impurity in l-tryptophan reported to be associated with eosinophilia-myalgia syndrome. Arch Toxicol. 1995;69:444–449
  130. Patmas MA. Eosinophilia-myalgia syndrome not associated with l-tryptophan. N J Med. 1992;89:285–286
  131. Michelson D, Page SW, Casey R, et al. An eosinophilia-myalgia syndrome related disorder associated with exposure to l-5-hydroxytryptophan. J Rheumatol. 1994;21:2261–2265
  132. Martin RW, Duffy J, Engel AG, et al. The clinical spectrum of the eosinophilia-myalgia syndrome associated with l-tryptophan ingestion (Clinical features in 20 patients and aspects of pathophysiology). Ann Intern Med. 1990;113:124–134
  133. Smith MJ, Garrett RH. A heretofore undisclosed crux of eosinophilia-myalgia syndrome: compromised histamine degradation. Inflamm Res. 2005;54:435–450
  134. Slutsker L, Hoesly FC, Miller L, et al. Eosinophilia-myalgia syndrome associated with exposure to tryptophan from a single manufacturer. JAMA. 1990;264:213–217
  135. Belongia EA, Hedberg CW, Gleich GJ, et al. An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. N Engl J Med. 1990;323:357–365
  136. Kamb ML, Murphy JJ, Jones JL, et al. Eosinophilia-myalgia syndrome in l-tryptophan-exposed patients. JAMA. 1992;267:77–82
  137. Centers for Disease Control. Eosinophilia-myalgia syndrome and l-tryptophan-containing products—New Mexico, Minnesota, Oregon, New York, 1989. MMWR Morb Mortal Wkly Rep. 1989;38:785–788
  138. Eidson M, Philen RM, Sewell CM, et al. l-Tryptophan and eosinophilia-myalgia syndrome in New Mexico. Lancet. 1990;335:645–648
  139. Shapiro S. Epidemiologic studies of the association of l-tryptophan with the eosinophilia-myalgia syndrome: a critique. J Rheumatol. 1996;23(suppl 46):44–59
  140. Horwitz RI, Daniels SR. Bias or biology: evaluating the epidemiologic studies of l-tryptophan and the eosinophilia-myalgia syndrome. J Rheumatol. 1996;23(suppl 46):60–72
  141. Sullivan EA, Kamb ML, Jones JL, et al. The natural history of eosinophilia-myalgia syndrome in a tryptophan-exposed cohort in South Carolina. Arch Intern Med. 1996;156:973–979
  142. Pincus T. Eosinophilia-myalgia syndrome: patient status 2-4 years after onset. J Rheumatol Suppl. 1996;46:19–24
  143. Meyer K, Moller A, Karg C, et al. Formation and determination of aldehyde-addition products of tryptophan. Adv Exp Med Biol. 1996;398:711–717
  144. Trucksess MW, Thomas FS, Page SW. High-performance liquid chromatographic determination of 1,1′-ethylidenebis(l-tryptophan) in l-tryptophan preparations. J Pharm Sci. 1994;83:720–722
  145. Williamson BL, Tomlinson AJ, Hurth KM, et al. Rapid HPLC screening method for contaminants found in implicated l-tryptophan associated with eosinophilia myalgia syndrome and adulterated rapeseed oil associated with toxic oil syndrome. Biomed Chromatogr. 1998;12:255–261

 This article was published in: Barceloux DG. Medical Toxicology of Natural Substances: Foods, Fungi, Medicinal Herbs, Toxic Plants, and Venomous Animals. Hoboken, NJ: John Wiley & Sons, 2008. p. 5-21. Copyright © 2008 by John Wiley & Sons, Inc. Reprinted with permission of John Wiley & Sons, Inc.

PII: S0011-5029(09)00014-5

doi: 10.1016/j.disamonth.2009.01.003

Disease-A-Month
Volume 55, Issue 5 , Pages 263-291 , May 2009

Article Tools

* Image Usage & Resolution